Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label multicenter study of intraperitoneal YH01 injection for malignant ascites in advanced ovarian cancer
CTR20261906Phase 2Active
- Sponsor
- InmFuture
- Start
- May 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of YH01 in ovarian cancer and malignant ascites (2 arms), sponsored by InmFuture. Primary endpoint: Objective response rate of ascites. Started May 2026; status: active.
02
Drugs
YH01
03
Conditions
ovarian cancermalignant ascites
Beyond the preview
Go deeper on CTR20261906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261906.